Study of Tirzepatide and Ixekizumab Treatments for Psoriatic Arthritis and Overweight or Obesity

What this Trial Is About

Researchers are evaluating how weight loss achieved by tirzepatide or treatment with ixekizumab affects the skin, joint, and fat tissues in adults with Psoriatic Arthritis, Psoriasis, and a body mass index BMI of 27 or higher. The study aims to understand molecular changes in these tissues and how they relate to weight loss and disease activity. Participants have Psoriatic Arthritis diagnosed for at least six months and active disease. Participants will be randomly assigned to one of three groups receiving tirzepatide alone, ixekizumab alone, or a combination of both drugs. They will undergo ultrasound-guided synovial biopsies, skin biopsies, skin tape sampling, and fat biopsies at the start and at 12 weeks. Optional additional biopsies can be done at 36 weeks. Blood and urine samples will be collected at several time points up to 52 weeks. Those on tirzepatide who do not achieve minimal disease activity may be offered ixekizumab at specified weeks. During the 52-week study, disease activity will be monitored through examinations and questionnaires. Samples collected at various intervals will be used to assess molecular changes linked to weight loss and immunomodulation. The main measure is molecular changes in tissue biopsies at 12 weeks, with secondary measures including blood molecular changes and comparisons between treatments. Safety and disease activity are closely followed throughout the trial.

Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis